The dissolution of limited company by valid reason
Is this your thesis?
This record came from a bulk archive import. If it’s yours, link it to your profile.
Abstract (EN)
Article 636/III of the Turkish Commercial Code No. 6102 regulates that in limited liability companies, each partner has the right to request the termination of the partnership from the court in the presence of valid reasons. The regulation further states that instead of deciding on the termination of the company, the court may order the payment of the plaintiff partner's share at its true value and the removal of the plaintiff from the partnership, or it may impose an appropriate and acceptable alternative solution. In this study, the concept of valid reason under this provision, which is one of the termination cases of a limited liability company, is explained, and the circumstances that constitute valid reasons requiring the termination of a limited liability company are examined. Additionally, the study focuses on alternative solutions that the court may decide within the framework of its discretion when valid reasons exist, and in the event that termination is decided as a last resort, it discusses the consequences of this situation and the procedural aspects of the litigation.
Author
Pınar Koşan
How to Cite
Pınar Koşan (Master Thesis). The dissolution of limited company by valid reason, 2023, Yeditepe University.
Keywords
License
Tüm Hakları Saklıdır
This work is shared under the specified license terms.
More theses from Yeditepe University
- Washington ambassadors in Turkish-US relations (1927-1960)(2023)
- The relationship between mindfulness and sleep quality: The mediating role of smartphone addiction and bedtime procrastination(2023)
- Metamorphosis of female voices: A study of the violation of women in Greek and Roman mythology and feminist rewritings reclaiming the narrative(2022)
- The relationship between machiavelism, grandiose and vulnerable narcissism, and loneliness among white collar workers(2023)
- Evaluation of drug-drug interaction checkers along clinically relevant adverse drug events in oncology and hematology pediatric patients(2023)
- Declaration obligation of the insurant during the conclusion of the contract(2021)